CA2533752A1 - Use of quinazoline tyrosine kinase inhibitors in the treatment of inflammatory processes - Google Patents
Use of quinazoline tyrosine kinase inhibitors in the treatment of inflammatory processes Download PDFInfo
- Publication number
- CA2533752A1 CA2533752A1 CA002533752A CA2533752A CA2533752A1 CA 2533752 A1 CA2533752 A1 CA 2533752A1 CA 002533752 A CA002533752 A CA 002533752A CA 2533752 A CA2533752 A CA 2533752A CA 2533752 A1 CA2533752 A1 CA 2533752A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- quinazoline
- methoxy
- chloro
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The invention relates to the use of selected quinazolines, tautomers, stereoisomeres and salts thereof, especially the physiologically compatible salts thereof with inorganic or organic acids or bases, in the production of a medicament for the prophylaxis or treatment of illnesses of the respiratory tracts or lungs and additional inflammatory illnesses.
Description
Boehringer Ingelheim Case 1/1537-Ro D-55216 INGELHEIM foreign filing text 84562fft.210 Use of tyrosine kinase inhibitors for the treatment of inflammatory processes The present invention relates to the use of quinazolines selected from the group consisting of ~o (1) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline, (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]-amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (3) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N,N-bis-(2-methoxy-ethyl)-amino]-oxo-2-buten-1-yl}amino)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (4) 4-[(3-ethynyl-phenyl)amino]-6-{[4-(5,5-dimethyl-2-oxo-morpholin-4-yl)-1-oxo-2-2o buten-1-yl]amino}-quinazoline, (5) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline, (6) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, (7) 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-6-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, (8) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{2-[4-(2-oxo-morpholin-4-yl)-piperidin-1-yl]-ethoxy}-7-methoxy-quinazoline, (9) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, (10) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, (11) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, (12) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, (13) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, (14) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline, (15) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(2-oxo-3-methyl-imidazolidin-2o yl)ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, (16) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(2-oxo-hexahydropyrimidin-1-yl)ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, (17) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, (18) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline and (19) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, for preparing a pharmaceutical composition for the prevention and treatment of diseases of the airways and lungs which are accompanied by increased or altered s production of mucus, e.g. in inflammatory diseases of the airways such as acute bronchitis, chronic bronchitis, chronic obstructive bronchitis (COPD), asthma, bronchiectasias, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, a1-an titrypsin deficiency, or coughs, pulmonary emphysema, pulmonary fibrosis or hyperreactive airways.
The compounds are also suitable for treating inflammatory diseases of the gastrointestinal tract or bile duct and gall bladder which are associated with disrupted activity of the tyrosine kinases, such as may be found e.g. in acute or chronic inflammatory changes such as cholecystitis, Crohn's disease, ulcerative colitis, and 1s ulcers or polyposis in the gastrointestinal tract or such as may occur in diseases of the gastrointestinal tract which are associated with increased secretions, such as Menetrier's disease, secreting adenomas and protein loss syndromes, and also for treating inflammatory diseases of the joints, such as rheumatoid arthritis, 2o inflammatory diseases of the skin, the eyes, in inflammatory pseudopolyps, in colitis cystica profunda or pneumatosis cystoides intestinalis.
Preferred fields of application are inflammatory diseases of the respiratory organs or of the intestine, such as chronic bronchitis (COPD), chronic sinusitis, asthma, 2s Crohn's disease, ulcerative colitis or polyposis of the intestines.
Particularly preferred fields of application are inflammatory diseases of the airways or lungs such as chronic bronchitis (COPD) or asthma.
3o The present invention further relates to a process for treating diseases of the airways and lungs which are accompanied by increased or altered production of mucus, e.g. in inflammatory diseases of the airways such as acute bronchitis, chronic bronchitis, chronic obstructive bronchitis (COPD), asthma, bronchiectasias, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, a1-antitrypsin deficiency, or coughs, pulmonary emphysema, pulmonary fibrosis and hyperreactive airways, s for treating inflammatory diseases of the gastrointestinal tract and bile duct and gall bladder which are associated with disrupted activity of the tyrosine kinases, such as may be found e.g. in acute or chronic inflammatory changes such as cholecystitis, Crohn's disease, ulcerative colitis and ulcers or polyposis in the gastrointestinal tract or such as may occur in diseases of the gastrointestinal tract which are associated ~o with increased secretions, such as Menetrier's disease, secreting adenomas and protein loss syndromes, and also for treating inflammatory diseases of the joints, such as rheumatoid arthritis, inflammatory diseases of the skin, the eyes, in inflammatory pseudopolyps, in colitis ~s cystica profunda and pneumatosis cystoides intestinalis, comprising administering an effective amount of one or more of the above-mentioned compounds (1 ) to (19) or optionally one of the physiologically acceptable salts thereof to a patient requiring such treatment.
In the process according to the invention the above-mentioned compounds are used in doses from 0.001-10 mg/kg body weight, for example 0.5 - 7.0 mg/kg, preferably 0.01-1.5 mg/kg, expediently administered 1 to 3 times a day.
The active substances may be administered by oral, buccal or parenteral route, by atomisation for inhalation, rectally or topically. They may be administered parenterally by subcutaneous, intravenous and intramuscular injections and infusion techniques.
Conventional formulations may be used for administering them, such as the 3o formulations mentioned above with regard to the active substances. For example, the active substances may be formulated, optionally together with other active substances, with one or more inert conventional carriers and/or diluents, e.g.
with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetyl stearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.
The active substances may be given orally in a variety of different dosage forms, i.e.
they may be prepared with various pharmaceutically acceptable inert carriers to form tablets, capsules, pastilles, lozenges, sweets, powders, sprays, aqueous suspensions, elixirs, syrups and the like. Such carriers include solid diluents or fillers, ~o sterile aqueous media and various non-toxic organic solvents. In addition, oral pharmaceutical preparations of this kind may be suitably sweetened or flavoured, using various agents conventionally used for this purpose. In general the active substances are present in oral formulations of this kind in concentrations ranging from about 0.5 to about 90 wt.%, based on the total composition, in amounts ~5 sufficient to produce the desired dosage units. Other suitable dosage forms for the active substances include preparations and devices with controlled release, with which the skilled man will be familiar.
For parenteral administration solutions of the active substances in sesame or 2o groundnut oil or in aqueous propyleneglycol as well as sterile aqueous solutions of the corresponding pharmaceutically acceptable salts may be used. Aqueous solutions of this kind should be suitably buffered as necessary and the liquid diluent may optionally be made isotonic with sufficient salt or glucose. These specific aqueous solutions are particularly suitable for intravenous, intramuscular and 25 subcutaneous injection. In this context, the sterile aqueous media used may easily be obtained by conventional methods well known to the skilled man. For example, distilled water is normally used as a liquid diluent, and the finished preparation is passed through a suitable bacterial filter, e.g. a filter made of sintered glass, kieselguhr or unglazed porcelain. Preferred filters of this type include Berkefeld, 3o Chamberland and asbestos disc metal Seitz filters, the liquid being aspirated into a sterile container using a suction pump. Throughout the entire process of preparing these injectable solutions the necessary steps should always be carried out in such a way as to obtain the end products in a sterile state. For transdermal administration the formulations of the particular compounds or compounds include for example solutions, lotions, ointments, creams, gels, suppositories, formulations for long-lasting speed-limited release preparations and devices therefor. These formulations comprise the particular compounds) and may contain ethanol, water, penetration promoters and inert carriers, e.g. gel-forming materials, mineral oil, emulsifiers, s benzyl alcohol and the like.
The substances may be administered by inhalation in the form of powder formulations with lactose and other excipients or in the form of aqueous solutions as an aerosol.
The inhalable powders which may be used according to the invention may contain the active substance or combination of active substances either on its own or in admixture with suitable physiologically acceptable excipients. If the active substance or combination of active substances is present in admixture with physiologically 1s acceptable excipients, the following physiologically acceptable excipients may be used to prepare these inhalable powders according to the invention:
monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextran), polyalcohols (e.g.
sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these excipients with one another. Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
2s Inhalation aerosols containing propellant gas which may be used according to the invention may contain the active substance or combination of active substances dissolved in the propellant gas or in dispersed form. The propellant gases which may be used to prepare the inhalation aerosols according to the invention are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such 3o as n-propane, n-butane or isobutane and halohydrocarbons such as preferably fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The propellant gases mentioned above may be used on their own or in mixtures thereof. Particularly preferred propellant gases are fluorinated alkane _7_ derivatives selected from TG134a (1,1,1,2-tetrafluoroethane), TG227 (1,1,1,2,3,3,3-heptafluoropropane) and mixtures thereof.
The propellant-driven inhalation aerosols which may be used according to the s invention may also contain other ingredients such as co-solvents, stabilisers, surface active agents (surfactants), antioxidants, lubricants and pH adjusters. All these ingredients are known in the art.
If the active substance or combination of active substances according to the invention is administered by inhalation in the form of propellant-free solutions or ~o suspension, aqueous or alcoholic, preferably ethanolic solutions may be used as the solvent. The solvent may be exclusively water or a mixture of water and ethanol.
The relative proportion of ethanol to water is not restricted, but the maximum limit is up to 70 percent by volume, more particularly up to 60 percent by volume and most preferably up to 30 percent by volume. The remainder of the volume is made up of ~5 water. The solutions or suspensions containing the active substance or combination of active substances are optionally adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. The pH may be adjusted using acids selected from inorganic or organic acids. Examples of particularly suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid.
Examples 20 of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, malefic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc. Preferred inorganic acids are hydrochloric acid and sulphuric acid. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. If desired, mixtures of the above acids may also be used, particularly in the case of 25 acids which have other properties in addition to their acidifying qualities, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example. According to the invention, it is particularly preferred to use hydrochloric acid to adjust the pH.
so As already mentioned hereinbefore, the compounds of general formula (I) and the salts thereof have valuable properties, particularly an anti-inflammatory activity.
_$_ For example, the compounds A = 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline, B = 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N,N-bis-(2-methoxy-ethyl)-amino]-oxo-2-buten-1-yl}amino)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, C = 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-~o ethoxy]-7-methoxy-quinazoline, D = 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline and E - 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-6-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline were tested as follows to investigate their anti-inflammatory activity:
2o Test 1: Inhibition of the smoke-induced accumulation of granulocytes in the lung tissue Lung indications: Inhibition of the cigarette smoke-induced influx of neutrophilic granulocytes into the lung tissue by the EGF-receptor kinase inhibitor 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline (compound A).
Method:
Male rats (strain: Sprague-Dawley) weighing from 250-300 g were exposed for 5 so days to the smoke from 8 cigarettes per day. The animals in the group treated with compound A, anaesthetised with isofluran, were given an intratracheal dose of 0.03 or 0.1 mg/kg of compound A in a volume of 0.05 ml each day 30 min before the start of the exposure to smoke. On the last day of the test the animals were killed 4 hours after the last exposure to smoke and the lung tissue was removed. A sample of _g_ 200 mg was taken from each lung and placed in a test tube prepared with 1 ml of 0.5% hexadecyltrimethylammonium bromide. The samples were homogenised for 15 sec using an Ultraturrax. The homogenised samples were centrifuged at 15700 g in an Eppendort bench centrifuge for 5 min at ambient temperature. 50 ml of the s supernatant was removed and mixed with 250 ml of phosphate buffer (50mmol/I) containing 0.197 mg/ml of O-dianisidine dihydrochloride. After 10 minutes' incubation at ambient temperature the absorption was measured with a spectral photometer at a wavelength of 450 nm.
The dosage which led to a 50% inhibition of the MPO activity (= ID50) was ~o determined by linear regression.
Results:
Exposure to cigarette smoke in rats led to an influx of neutrophilic granulocytes into the lung tissue, measured by the content of myeloperoxidase in the tissues, which is ~s specific for neutrophilic granulocytes. Intratracheal treatment of the animals with the EGFR kinase inhibitor A resulted in a significant (p<0.005) inhibition of the smoke-induced accumulation of granulocytes and thus produced an anti-inflammatory activity.
2o Further results are shown in the following Table:
active substanceID50 [mg/kg]
A 0.3 B 0.2 D 1.1 E 0.4
The compounds are also suitable for treating inflammatory diseases of the gastrointestinal tract or bile duct and gall bladder which are associated with disrupted activity of the tyrosine kinases, such as may be found e.g. in acute or chronic inflammatory changes such as cholecystitis, Crohn's disease, ulcerative colitis, and 1s ulcers or polyposis in the gastrointestinal tract or such as may occur in diseases of the gastrointestinal tract which are associated with increased secretions, such as Menetrier's disease, secreting adenomas and protein loss syndromes, and also for treating inflammatory diseases of the joints, such as rheumatoid arthritis, 2o inflammatory diseases of the skin, the eyes, in inflammatory pseudopolyps, in colitis cystica profunda or pneumatosis cystoides intestinalis.
Preferred fields of application are inflammatory diseases of the respiratory organs or of the intestine, such as chronic bronchitis (COPD), chronic sinusitis, asthma, 2s Crohn's disease, ulcerative colitis or polyposis of the intestines.
Particularly preferred fields of application are inflammatory diseases of the airways or lungs such as chronic bronchitis (COPD) or asthma.
3o The present invention further relates to a process for treating diseases of the airways and lungs which are accompanied by increased or altered production of mucus, e.g. in inflammatory diseases of the airways such as acute bronchitis, chronic bronchitis, chronic obstructive bronchitis (COPD), asthma, bronchiectasias, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, a1-antitrypsin deficiency, or coughs, pulmonary emphysema, pulmonary fibrosis and hyperreactive airways, s for treating inflammatory diseases of the gastrointestinal tract and bile duct and gall bladder which are associated with disrupted activity of the tyrosine kinases, such as may be found e.g. in acute or chronic inflammatory changes such as cholecystitis, Crohn's disease, ulcerative colitis and ulcers or polyposis in the gastrointestinal tract or such as may occur in diseases of the gastrointestinal tract which are associated ~o with increased secretions, such as Menetrier's disease, secreting adenomas and protein loss syndromes, and also for treating inflammatory diseases of the joints, such as rheumatoid arthritis, inflammatory diseases of the skin, the eyes, in inflammatory pseudopolyps, in colitis ~s cystica profunda and pneumatosis cystoides intestinalis, comprising administering an effective amount of one or more of the above-mentioned compounds (1 ) to (19) or optionally one of the physiologically acceptable salts thereof to a patient requiring such treatment.
In the process according to the invention the above-mentioned compounds are used in doses from 0.001-10 mg/kg body weight, for example 0.5 - 7.0 mg/kg, preferably 0.01-1.5 mg/kg, expediently administered 1 to 3 times a day.
The active substances may be administered by oral, buccal or parenteral route, by atomisation for inhalation, rectally or topically. They may be administered parenterally by subcutaneous, intravenous and intramuscular injections and infusion techniques.
Conventional formulations may be used for administering them, such as the 3o formulations mentioned above with regard to the active substances. For example, the active substances may be formulated, optionally together with other active substances, with one or more inert conventional carriers and/or diluents, e.g.
with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetyl stearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.
The active substances may be given orally in a variety of different dosage forms, i.e.
they may be prepared with various pharmaceutically acceptable inert carriers to form tablets, capsules, pastilles, lozenges, sweets, powders, sprays, aqueous suspensions, elixirs, syrups and the like. Such carriers include solid diluents or fillers, ~o sterile aqueous media and various non-toxic organic solvents. In addition, oral pharmaceutical preparations of this kind may be suitably sweetened or flavoured, using various agents conventionally used for this purpose. In general the active substances are present in oral formulations of this kind in concentrations ranging from about 0.5 to about 90 wt.%, based on the total composition, in amounts ~5 sufficient to produce the desired dosage units. Other suitable dosage forms for the active substances include preparations and devices with controlled release, with which the skilled man will be familiar.
For parenteral administration solutions of the active substances in sesame or 2o groundnut oil or in aqueous propyleneglycol as well as sterile aqueous solutions of the corresponding pharmaceutically acceptable salts may be used. Aqueous solutions of this kind should be suitably buffered as necessary and the liquid diluent may optionally be made isotonic with sufficient salt or glucose. These specific aqueous solutions are particularly suitable for intravenous, intramuscular and 25 subcutaneous injection. In this context, the sterile aqueous media used may easily be obtained by conventional methods well known to the skilled man. For example, distilled water is normally used as a liquid diluent, and the finished preparation is passed through a suitable bacterial filter, e.g. a filter made of sintered glass, kieselguhr or unglazed porcelain. Preferred filters of this type include Berkefeld, 3o Chamberland and asbestos disc metal Seitz filters, the liquid being aspirated into a sterile container using a suction pump. Throughout the entire process of preparing these injectable solutions the necessary steps should always be carried out in such a way as to obtain the end products in a sterile state. For transdermal administration the formulations of the particular compounds or compounds include for example solutions, lotions, ointments, creams, gels, suppositories, formulations for long-lasting speed-limited release preparations and devices therefor. These formulations comprise the particular compounds) and may contain ethanol, water, penetration promoters and inert carriers, e.g. gel-forming materials, mineral oil, emulsifiers, s benzyl alcohol and the like.
The substances may be administered by inhalation in the form of powder formulations with lactose and other excipients or in the form of aqueous solutions as an aerosol.
The inhalable powders which may be used according to the invention may contain the active substance or combination of active substances either on its own or in admixture with suitable physiologically acceptable excipients. If the active substance or combination of active substances is present in admixture with physiologically 1s acceptable excipients, the following physiologically acceptable excipients may be used to prepare these inhalable powders according to the invention:
monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextran), polyalcohols (e.g.
sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these excipients with one another. Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
2s Inhalation aerosols containing propellant gas which may be used according to the invention may contain the active substance or combination of active substances dissolved in the propellant gas or in dispersed form. The propellant gases which may be used to prepare the inhalation aerosols according to the invention are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such 3o as n-propane, n-butane or isobutane and halohydrocarbons such as preferably fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The propellant gases mentioned above may be used on their own or in mixtures thereof. Particularly preferred propellant gases are fluorinated alkane _7_ derivatives selected from TG134a (1,1,1,2-tetrafluoroethane), TG227 (1,1,1,2,3,3,3-heptafluoropropane) and mixtures thereof.
The propellant-driven inhalation aerosols which may be used according to the s invention may also contain other ingredients such as co-solvents, stabilisers, surface active agents (surfactants), antioxidants, lubricants and pH adjusters. All these ingredients are known in the art.
If the active substance or combination of active substances according to the invention is administered by inhalation in the form of propellant-free solutions or ~o suspension, aqueous or alcoholic, preferably ethanolic solutions may be used as the solvent. The solvent may be exclusively water or a mixture of water and ethanol.
The relative proportion of ethanol to water is not restricted, but the maximum limit is up to 70 percent by volume, more particularly up to 60 percent by volume and most preferably up to 30 percent by volume. The remainder of the volume is made up of ~5 water. The solutions or suspensions containing the active substance or combination of active substances are optionally adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. The pH may be adjusted using acids selected from inorganic or organic acids. Examples of particularly suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid.
Examples 20 of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, malefic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc. Preferred inorganic acids are hydrochloric acid and sulphuric acid. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. If desired, mixtures of the above acids may also be used, particularly in the case of 25 acids which have other properties in addition to their acidifying qualities, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example. According to the invention, it is particularly preferred to use hydrochloric acid to adjust the pH.
so As already mentioned hereinbefore, the compounds of general formula (I) and the salts thereof have valuable properties, particularly an anti-inflammatory activity.
_$_ For example, the compounds A = 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline, B = 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N,N-bis-(2-methoxy-ethyl)-amino]-oxo-2-buten-1-yl}amino)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, C = 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-~o ethoxy]-7-methoxy-quinazoline, D = 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline and E - 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-6-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline were tested as follows to investigate their anti-inflammatory activity:
2o Test 1: Inhibition of the smoke-induced accumulation of granulocytes in the lung tissue Lung indications: Inhibition of the cigarette smoke-induced influx of neutrophilic granulocytes into the lung tissue by the EGF-receptor kinase inhibitor 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline (compound A).
Method:
Male rats (strain: Sprague-Dawley) weighing from 250-300 g were exposed for 5 so days to the smoke from 8 cigarettes per day. The animals in the group treated with compound A, anaesthetised with isofluran, were given an intratracheal dose of 0.03 or 0.1 mg/kg of compound A in a volume of 0.05 ml each day 30 min before the start of the exposure to smoke. On the last day of the test the animals were killed 4 hours after the last exposure to smoke and the lung tissue was removed. A sample of _g_ 200 mg was taken from each lung and placed in a test tube prepared with 1 ml of 0.5% hexadecyltrimethylammonium bromide. The samples were homogenised for 15 sec using an Ultraturrax. The homogenised samples were centrifuged at 15700 g in an Eppendort bench centrifuge for 5 min at ambient temperature. 50 ml of the s supernatant was removed and mixed with 250 ml of phosphate buffer (50mmol/I) containing 0.197 mg/ml of O-dianisidine dihydrochloride. After 10 minutes' incubation at ambient temperature the absorption was measured with a spectral photometer at a wavelength of 450 nm.
The dosage which led to a 50% inhibition of the MPO activity (= ID50) was ~o determined by linear regression.
Results:
Exposure to cigarette smoke in rats led to an influx of neutrophilic granulocytes into the lung tissue, measured by the content of myeloperoxidase in the tissues, which is ~s specific for neutrophilic granulocytes. Intratracheal treatment of the animals with the EGFR kinase inhibitor A resulted in a significant (p<0.005) inhibition of the smoke-induced accumulation of granulocytes and thus produced an anti-inflammatory activity.
2o Further results are shown in the following Table:
active substanceID50 [mg/kg]
A 0.3 B 0.2 D 1.1 E 0.4
Claims (8)
1. Use of quinazolines selected from the group consisting of (1) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline, (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]-amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (3) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N,N-bis-(2-methoxy-ethyl)-amino]-oxo-2-buten-1-yl}amino)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (4) 4-[(3-ethynyl-phenyl)amino]-6-{[4-(5,5-dimethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-quinazoline, (5) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline, (6) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, (7) 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-6-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, (8) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{2-[4-(2-oxo-morpholin-4-yl)-piperidin-1-yl]-ethoxy}-7-methoxy-quinazoline, (9) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, (10) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, (11) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, (12) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, (13) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, (14) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline, (15) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(2-oxo-3-methyl-imidazolidin-yl)ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, (16) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(2-oxo-hexahydropyrimidin-1-yl)ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, (17) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, (18) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline and (19) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, for preparing a pharmaceutical composition for the prevention and treatment of diseases of the airways and lungs which are accompanied by increased or altered production of mucus, inflammatory diseases of the gastrointestinal tract or bile duct or gall bladder which are associated with disrupted activity of the tyrosine kinases, inflammatory diseases of the joints, inflammatory diseases of the skin, the eyes, inflammatory pseudopolyps, colitis cystica profunda or pneumatosis cystoides intestinalis.
2. Use according to claim 1, characterised in that it is a treatment of the upper and lower respiratory organs or of the intestines.
3. Use according to claim 2, characterised in that the diseases are COPD, chronic sinusitis, asthma, cystic fibrosis, Crohn's disease, ulcerative colitis or polyposis of the intestine.
4. Use according to claim 3, characterised in that the diseases are COPD, asthma or cystic fibrosis.
5. Method of treating diseases of the airways and lungs which are accompanied by increased or altered production of mucus, inflammatory diseases of the gastrointestinal tract or bile duct or gall bladder which are associated with disrupted activity of the tyrosine kinases, inflammatory diseases of the joints, inflammatory diseases of the skin, the eyes, inflammatory pseudopolyps, colitis cystica profunda or pneumatosis cystoides intestinalis, comprising administering an effective amount of a quinazoline selected from the group consisting of (1) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-methoxy-quinazoline, (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]-amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (3) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N,N-bis-(2-methoxy-ethyl)-amino]-oxo-2-buten-1-yl}amino)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (4) 4-[(3-ethynyl-phenyl)amino]-6-{[4-(5,5-dimethyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-quinazoline, (5) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline, (6) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, (7) 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-6-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, (8) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{2-[4-(2-oxo-morpholin-4-yl)-piperidin-1-yl]-ethoxy}-7-methoxy-quinazoline, (9) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, (10) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[cis-4-(N-acetyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, (11) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-methylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, (12) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[trans-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexan-1-yloxy]-7-methoxy-quinazoline, (13) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-dimethylamino-cyclohexan-1-yloxy)-7-methoxy-quinazoline, (14) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(trans-4-{N-[(morpholin-4-yl)carbonyl]-N-methyl-amino}-cyclohexan-1-yloxy)-7-methoxy-quinazoline, (15) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(2-oxo-3-methyl-imidazolidin-yl)ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, (16) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{1-[2-(2-oxo-hexahydropyrimidin-1-yl)ethyl]-piperidin-4-yloxy}-7-methoxy-quinazoline, (17) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(2-(2,2-dimethyl-6-oxo-morpholin-4-yl)-ethoxy]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, (18) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-methanesulphonyl-piperidin-4-yloxy)-7-methoxy-quinazoline and (19) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-(1-cyano-piperidin-4-yloxy)-7-methoxy-quinazoline, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, to a patient requiring such treatment.
6. Method according to claim 5, characterised in that it is a treatment of the upper and lower respiratory organs or of the intestines.
7. Method according to claim 6, characterised in that the diseases are COPD, chronic sinusitis, asthma, cystic fibrosis, Crohn's disease, ulcerative colitis or polyposis of the intestine.
8. Method according to claim 7, characterised in that the diseases are COPD, asthma or cystic fibrosis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10334226A DE10334226A1 (en) | 2003-07-28 | 2003-07-28 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| DE10334226.5 | 2003-07-28 | ||
| PCT/EP2004/008185 WO2005011701A1 (en) | 2003-07-28 | 2004-07-22 | Use of quinazoline tyrosine kinase inhibitors in the treatment of inflammatory processes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2533752A1 true CA2533752A1 (en) | 2005-02-10 |
Family
ID=34071934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002533752A Abandoned CA2533752A1 (en) | 2003-07-28 | 2004-07-22 | Use of quinazoline tyrosine kinase inhibitors in the treatment of inflammatory processes |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1651228A1 (en) |
| JP (1) | JP2007500156A (en) |
| CA (1) | CA2533752A1 (en) |
| DE (1) | DE10334226A1 (en) |
| WO (1) | WO2005011701A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007009265A (en) * | 2005-02-04 | 2007-09-07 | Boehringer Ingelheim Int | Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis. |
| TW200640904A (en) * | 2005-02-26 | 2006-12-01 | Astrazeneca Ab | Quinazoline derivatives |
| TWI385174B (en) | 2008-11-10 | 2013-02-11 | Nat Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
| WO2017141271A1 (en) * | 2016-02-17 | 2017-08-24 | Sun Pharmaceutical Industries Ltd. | Stable pharmaceutical composition of afatinib |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10042058A1 (en) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| DE10042059A1 (en) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| US6656946B2 (en) * | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6653305B2 (en) * | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| DE10063435A1 (en) * | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazoline derivatives, pharmaceuticals containing these compounds, their use and process for their preparation |
| US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| DE10231711A1 (en) * | 2002-07-13 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors or respiratory or gastrointestinal diseases |
| EA009300B1 (en) * | 2002-03-30 | 2007-12-28 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | 4-(n-phenylamino)-quinazolines/quinolines as tyrosine kinase inhibitors |
| DE10214412A1 (en) * | 2002-03-30 | 2003-10-09 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and process for their preparation |
-
2003
- 2003-07-28 DE DE10334226A patent/DE10334226A1/en not_active Withdrawn
-
2004
- 2004-07-22 WO PCT/EP2004/008185 patent/WO2005011701A1/en not_active Application Discontinuation
- 2004-07-22 JP JP2006521478A patent/JP2007500156A/en active Pending
- 2004-07-22 EP EP04763394A patent/EP1651228A1/en not_active Withdrawn
- 2004-07-22 CA CA002533752A patent/CA2533752A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE10334226A1 (en) | 2005-02-17 |
| WO2005011701A1 (en) | 2005-02-10 |
| EP1651228A1 (en) | 2006-05-03 |
| JP2007500156A (en) | 2007-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090306072A1 (en) | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | |
| US20070004720A1 (en) | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | |
| US8431585B2 (en) | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | |
| US20070099918A1 (en) | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy | |
| US20030158196A1 (en) | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | |
| CA2667543A1 (en) | New pharmaceutical combinations for treatment of respiratory and gastrointestinal disorders | |
| KR20080067643A (en) | Novel pharmaceutical combinations for the treatment of respiratory disorders | |
| CA2543649A1 (en) | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | |
| US20050059661A1 (en) | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | |
| JP2009523700A (en) | Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis | |
| CA2533752A1 (en) | Use of quinazoline tyrosine kinase inhibitors in the treatment of inflammatory processes | |
| AU2003206881B2 (en) | New medicinal compositions on the basis of anticholinergic agents and EGFR kinase inhibitors | |
| DE102005005505A1 (en) | Use of quinazoline derivatives e.g. 4-((3-chloro-4-fluoro-phenyl)amino)-6-(1-methanesulfonyl-piperidin-4-yloxy)-7-methoxy-quinazoline, which are tyrosine kinase inhibitors, to prevent or treat symptoms of e.g. chronic rhinosinusitis | |
| JP2004511542A (en) | Use of p38 inhibitors for the treatment of smoke inhalation | |
| US20120041043A1 (en) | Sulfonamide Compounds for the Treatment of Respiratory Disorders | |
| WO2023003468A1 (en) | Novel inhibitors of histone deacetylase (hdac), and methods, compositions and uses related thereto. | |
| WILSON et al. | Proceedings ofthe British Thoracic Society | |
| JPWO2006118169A1 (en) | Anti-asthma drug comprising PGD2 receptor antagonist and leukotriene receptor antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |